Johnson & Johnson (JNJ): pharma exposure

How global shocks reach JNJ

None of the tracked sector channels map to Johnson & Johnson (Pharmaceuticals), so only geography applies. Stories centered on the United States register as exposure, because the company is registered in the United States.

Direction is a tendency across cycles, not a forecast. Sector mapping uses the Finnhub industry classification; geography uses country of registration, not revenue by region.

What actually moves Johnson & Johnson

J&J's coupon exposure is the commercial paper and the near maturities, not the whole stack. Long-term debt was $41.4 billion after notes issued for the Intra-Cellular deal. About $2.0 billion of that is due in 2026. Commercial paper was $6.5 billion at a 3.81% average rate and rolls roughly every two months. The notes themselves are fixed. Cash also earns interest, so the net effect of a rate move is smaller than the gross debt suggests.

Trade already showed up in MedTech costs. The filing blames tariffs, along with currency, for a higher cost of products sold in that segment in 2025. The United States was 57% of sales, Europe 23%, and Asia-Pacific and Africa 15%. Conflict and US-China tension are named, and China volume-based procurement already pressures device prices.

The less obvious exposures are legal and organizational. After a Texas court dismissed the Red River talc case, J&J reversed about $7 billion of reserve and went back to litigating, with about $3.4 billion still reserved. It also plans to separate Orthopaedics, announced in October 2025. Neither item is a macro shock. Three wholesalers were about 48% of gross revenues.

Drawn from the annual filing cited below. Not a forecast and not investment advice.

What Johnson & Johnson sells and where it earns

Johnson & Johnson reports two segments: prescription drugs and medical devices. In the fiscal year ended December 28, 2025 sales were $94.2 billion, up 6.0%. Innovative Medicine, the drug unit, sold $60.4 billion, or 64%, led by oncology at $25.4 billion. DARZALEX for multiple myeloma alone accounted for about 15% of total revenue. MedTech sold $33.8 billion, or 36%, across surgery, orthopaedics, cardiovascular and vision, and cardiovascular grew fastest with help from Abiomed and Shockwave. The U.S. produced $53.8 billion, or 57% of sales. Europe was 23%, Asia-Pacific and Africa 15% and the rest of the Western Hemisphere 5%. Two issues dominate the filing. STELARA, once the top seller, fell 41% to $6.1 billion as biosimilars launched, which took roughly 6.2 points off worldwide operational growth. And after a Texas bankruptcy court dismissed the Red River talc case in March 2025, the company reversed about $7 billion of its talc reserve and returned to litigating the claims in court, leaving a reserve of about $3.4 billion. In October 2025 it also announced plans to separate its Orthopaedics business.

Customer concentration

Sales run through a few U.S. distributors. The filing says that in 2025 "the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues," about the same 48% in aggregate as in 2024 (20.5%, 15.6% and 12.3%).

Debt

Long-term debt, including the current portion, was $41.4 billion at December 28, 2025, up from $32.4 billion a year earlier after about $9.2 billion of notes were issued to fund the Intra-Cellular Therapies acquisition. Of that, $2.0 billion is due in 2026. Short-term borrowings and the current portion of long-term debt totaled about $8.5 billion, including $6.5 billion of commercial paper at a 3.81% weighted average rate. The notes listed in the debt note all carry fixed coupons, while the commercial paper rolls over roughly every two months.

Risk factors that moved this year

• Orthopaedics separation. A new section covers the planned separation announced in October 2025, targeted for completion 18 to 24 months later. The filing warns it may not happen on the expected terms or timeline, will carry significant costs and could make the share price more volatile.
• Tariffs. The warning that the U.S. may pause, reimpose or increase tariffs and that affected countries may retaliate carries over from the prior-year filing, but tariffs now show up in results: the MD&A blames tariffs, along with currency, for a higher cost of products sold in MedTech in 2025.
• Talc litigation is prominent rather than new. With the Red River bankruptcy dismissed, ovarian cancer trials are being scheduled in state courts through 2026 and beyond, and the company warns it could pay settlements or judgments above its accruals.

How this changes the exposure read

J&J sits under Health Care, which a template treats as defensive, and mostly it is. Trade and tariffs are the live channel: the filing blames tariffs for higher MedTech costs in 2025 and warns they could rise. Conflict risk comes through the Russia-Ukraine war, the Middle East and U.S.-China tensions, which the filing names, and China volume-based procurement already squeezes MedTech pricing. Rates and the Fed matter modestly through $6.5 billion of commercial paper and interest earned on cash. Oil shocks and chip or export rules are minor cost issues. Credit stress mostly means wholesaler exposure, with three distributors at about 48% of gross revenues.

Source: Johnson & Johnson 10-K, FY2025. Checked 2026-10-07. Figures are from the filing and may differ from the live stats above.

What is moving it now

Key stats

Recent filings

Related tickers